exendin-4 tirzepatide Amino acid sequence of in comparison to native GIP, GLP-1, The peptide “exedin-4” was first
Description
doi: 10.1111/dom.14496 48 ChavdaVPAjabiyaJTeliDBojarskaJApostolopoulosV
This distinction matters for dosing because compounded tirzepatide arrives in multi-dose vials rather than pre-filled pens
Tirzepatide is a dual GIP/GLP-1 agonist
A vial labeled 20 mg/mL packs twice as much peptide into the same volume
In practical terms, that means it helps drive appetite suppression, improved satiety, slowed gastric emptying, and broader metabolic effects that go beyond what older single-pathway GLP-1 compounds were able to do
Educate Clients : Be transparent with patients about the changes and how they may impact their treatment options
